Pharmaceutical

The University of Texas at Tyler broke ground on the $26.5 million W.T. Brookshire Hall in late April of 2014. The three-story, 60,000-sf facility will house the Ben and Maytee Fisch College of Pharmacy. Designed to encourage student-faculty interaction and support innovative pedagogies, the project will provide flexible classrooms, research labs, skills training suites, offices, and study areas. Completion is expected in May of 2015.

WuXi Biologics began building a $150 million mammalian cell culture manufacturing facility in April of 2015 in Wuxi, China. Designed to utilize disposable bioreactors, the biopharmaceutical production plant will be the largest of its kind in the world and will be able to run continuous or semi-continuous manufacturing processes in addition to traditional modes. Completion is expected by January of 2017. WuXi Biologics is a wholly owned subsidiary of WuXi PharmaTech.

Pharmaceutical products manufacturer Bath ASU is expanding their existing campus in the United Kingdom with the construction of a 21,500-sf production plant in Corsham. Designed by Pegasus, the project will triple available cleanroom space and is being built by John Yerbury Property Developments using Kingspan Micro-Rib insulated metal wall panels. Completion is expected by June of 2015.

360 Pharma Group will begin construction in late spring of 2015 on a 300,000-sf headquarters and distribution facility in Mason, Ohio. Sited on a 47-acre campus, the $16 million project will provide office and warehouse space and will accommodate approximately 225 employees. Occupancy is expected in summer of 2016. 360 Pharma Group is the parent company of Masters Pharmaceutical, MHC Medical Products, and logistics firm RxTPL.

Nanotherapeutics is building the $135 million Advanced Development and Manufacturing Center in Alachua, Fla. Designed by RS&H, the 165,000-sf project will support vaccine development and production utilizing advanced biomanufacturing technologies. Ground was broken on the facility in October of 2013 and completion is expected by 2016. Nanotherapeutics is contracted to the Department of Defense to develop medical countermeasures to chemical and biological threats as well as infectious disease outbreaks.

Researchers at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have completed a study of a therapeutic candidate for the Marburg virus in a BSL-4 research facility in Fort Belvoir, Va. The study was conducted entirely under Good Laboratory Practices (GLP) conditions, setting a precedent for GLP testing of medical products for BSL-4 pathogens. This may facilitate rapid evaluation and licensing by the Food and Drug Administration (FDA).

The 89,700-sf, seven-story expansion of the Wistar Institute increases research space from 30 to 45 labs, with new support areas, including tissue culture rooms, fume hood alcoves, equipment alcoves, and a shared cold room. Each of the five lab floors contains an open-plan research lab for four professors and their research teams of 35 to 40 to work collaboratively on cancer research, genetics, and vaccine development. Flexible, moveable lab benches will accommodate changing research needs.

GlaxoSmithKline is building an active pharmaceutical ingredients manufacturing plant in Montrose in the United Kingdom. Doosan Babcock was awarded the $37 million construction contract for the project, which is expected to be fully operational in summer of 2016. The three-story, 291,000-sf facility will support the production of therapeutic agents for respiratory conditions.

The four-story, 80,000-sf Research and Graduate Education Complex on the campus of Northeast Ohio Medical University (NEOMED) is a state-of-the-art biomedical research facility for researchers from the colleges of Pharmacy, Medicine, and Graduate Studies. Three floors of laboratories and support spaces house more than 30 scientists and their teams, with space for 156 bench researchers. The building also contains office space for faculty, write-up areas for research staff and students, and small-group teaching and seminar rooms.

The National University of Ireland Galway began construction in January of 2015 on the 88,000-sf Human Biology Building. Designed by Scott Talon Walker Architects, the five-story teaching and research facility will provide labs, lecture halls, and offices for the departments of anatomy, physiology, and pharmacology. The Human Biology Building will also include a vivarium, a microscopy suite, and anatomy and mortuary space. The construction cost of the project is $34 million and the general contractor is BAM Group Ireland.

Fujifilm Diosynth Biotechnologies broke ground in January of 2015 on a 62,000-sf biopharmaceutical manufacturing facility in Research Triangle Park, N.C. Designed to support collaborative research and development, the three-story BioProcess Innovation Center will accommodate the creation and production of advanced proteins, vaccines, and monoclonal antibodies. The project team includes Alexandria Real Estate Equities and KBR Building Group. Completion is expected in late 2015.

The University of North Texas Health Science Center (UNTHSC) renovated two floors of its Research and Education Building to accommodate a new College of Pharmacy program and the associated accreditation requirements. The spaces include both instructional and research labs.

The three-story International Vaccine Centre (InterVac) at the University of Saskatchewan is one of the largest vaccine research centers in the world and the largest in North America. It is connected by a walkway to the Vaccine and Infectious Disease Organization (VIDO) laboratory building in a cluster of life sciences R&D facilities at the University. The facilities operate together as VIDO-InterVac, one of only a few BSL-3 facilities in the world that can accommodate disease and vaccine research involving animals as large as cows.

Stelis Biopharma has selected Bio-XCell to construct a $60 million biopharmaceutical manufacturing facility in Nusajaya in the Johor region of Malaysia. Providing mammalian and microbial production suites, the 140,000-sf project will feature next-generation, single-use bioprocessing technologies. Completion is expected in late 2016 with operations commencing in mid-2017. Stelis Biopharma is a wholly-owned subsidiary of Strides Arcolab.

Biotrial is constructing the Clinical Pharmacology Unit in Newark, N.J. Located adjacent to Rutgers New Jersey Medical School in the University Heights Science Park, the 60,000-sf facility will support early development clinical studies in association with University Hospital. The project was designed by Francis Cauffman and is being built by Joseph A. Natoli Construction. Occupancy is expected in mid-2015.